Popular search terms:
Search Results
123 results found-
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
CSL Behring Australia's Product Information (PI), Consumer Medicine Information (CMI), Safety Data Sheets and New Zealand Data Sheet
https://www.cslbehring.com.au/products/products-list -
Intragam P NZ DS 15.00 Page 3 of 13 NEW ZEALAND DATA SHEET Acute Renal Failure There have been occasional reports of renal dysfunction and acute renal failure in patients receiving IVIg products.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/intragam-p-nz-ds-v1500.pdf -
Patients with anti-IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be switched to Hizentra® only under close medical supervision.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/hizentra-product-information-1200.pdf -
In general, all patients treated with coagulation FVIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds1900.pdf -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/thrombotrolvf-au-pi-1000.pdf -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/hepatitis-b-imigvf-au-pi-900.pdf